Familial Amyloidosis [1 gene]

Related to transthyretin [TTR]

Amyloidosis is a generic term referring to a group of diseases characterized by extracellular deposition of amyloid material in various organs, either in isolation or generalized. Clinical manifestations depend on the affected organ and the amount of deposited amyloid. Amyloidosis is estimated in 1 in 60,000 people, with 0.8% prevalence in autopsies.

The deposition of amyloid is common on the cardiac level, and it may be the first manifestation of the disease. The presentation is usually left ventricular hypertrophy, therefore patients may be initially diagnosed as suffering from hypertrophic cardiomyopathy. There is a familial amyloid cardiomyopathy (autosomal dominant inheritance pattern) caused by mutations in the transthyretin gene (TTR). Over 100 mutations associated with different phenotypes, including neuropathic, cardiac, renal and ocular forms, have been described in this gene. The prevalence of this disease is unknown.

  • Patients with clinical diagnosis and positive anatomopathologic study for familial amyloidosis in which transthyretin/prealbumin (TTR) protein has been found responsible.
  • Patients under suspicion of familial amyloidosis related to TTR.
  • Familial study: A search for the mutation previously identified in a proband (relatives of patients with familial TTR amyloidosis in which a pathogenic mutation has been previously identified).

In case a clear diagnosis of familial TTR amyloidosis exists, the genetic study allows identifying the causal mutation in over 99% of cases.

The great majority of them are point mutations, with no deletion/duplication-type structural variants having been described in this gene.

Request study Informed consent
Steps to follow
Steps to follow

How to order

1. Download & fill out

Please cover as many fields as possible in both documents

2. Sample collection

Three sample types: saliva, peripheral blood or genomic DNA

3. Pack the sample

Please pack the sample in a way to prevent leakage

4. Send the sample & the request

Please schedule the delivery for Mon–Thur: 8am – 5pm

5. Result: the report

Via: Client Site HIC / Client Site Imegen / Certified email

Ask for information
Solicita información de

Familial Amyloidosis

  • *

Turnaround time (TAT): 4 weeks

Ref. S-201702765

Familial Amyloidosis: View panel

  • TTR gene sequencing is recommended for individuals with a clear suspicion of familial amyloidosis.

  • TTR

Priority Genes : Genes where there is sufficient evidence (clinical and functional) to consider them associated with the disease; they are included in the clinical practice guidelines.
Secondary Genes: Genes related to the disease, but with a lower level of evidence or that constitute sporadic cases.
* Candidate Genes: Not enough evidence in humans, but potentially associated with the disease.

Related panels
Hypertrophic Cardiomyopathy – Basic Panel [18 genes]

Panel that include TTR gene

Hypertrophic Cardiomyopathy – Extended Panel [118 genes]

Panel that include TTR gene

Cardiomyopathies General Panel [204 genes]

Panel that include TTR gene

References

  • Familial Transthyretin Amyloidosis. Yoshiki Sekijima, Kunihiro Yoshida, Takahiko Tokuda and Shu-ichi Ikeda. GeneReviews. 2012 January 26.

This site is registered on wpml.org as a development site.